Clinical Trials Logo

Neoplasm Metastasis clinical trials

View clinical trials related to Neoplasm Metastasis.

Filter by:

NCT ID: NCT00377780 Terminated - Breast Cancer Clinical Trials

Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast Cancer

MYOHERTAX
Start date: August 2006
Phase: Phase 2
Study type: Interventional

This is an open phase II study evaluating the efficacy and safety of the non pegylated liposomal doxorubicin (Myocet®), trastuzumab (Herceptin®), and docetaxel (Taxotere®) combination as first-line treatment of patients with metastatic HER2/neu positive breast cancer.

NCT ID: NCT00377559 Completed - Breast Cancer Clinical Trials

Liposomal Doxorubicin and Docetaxel in HER2 Negative Metastatic Breast Cancer

MYOTAX
Start date: May 2006
Phase: Phase 2
Study type: Interventional

This is an open phase II multicentre study evaluating the efficacy and safety of the non pegylated liposomal doxorubicin (Myocet®) and docetaxel (Taxotere®) combination as first-line treatment of patients with metastatic HER2/neu negative breast cancer.

NCT ID: NCT00376519 Terminated - Lymphoma Clinical Trials

Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases

Start date: May 2007
Phase: Phase 1
Study type: Interventional

RATIONALE: Giving chemotherapy, such as fludarabine and cyclophosphamide, and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells and prepares the patient's bone marrow for the stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer or abnormal cells (graft-versus-tumor effect). Giving an infusion of the donor's T-regulatory cells before the transplant may help increase this effect. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after the transplant may stop this from happening. PURPOSE: This phase I trial is studying the side effects and best dose of umbilical cord blood T-regulatory cell infusion followed by donor umbilical cord blood transplant in treating patients with high-risk leukemia or other hematologic diseases.

NCT ID: NCT00375830 Completed - Cancer Clinical Trials

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

Start date: January 2006
Phase: Phase 2
Study type: Interventional

This clinical trial studies the use of sodium fluorine-18 (18F-NaF) plus fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/ whole body magnetic resonance imaging (WBMRI) to detect skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer.

NCT ID: NCT00375648 Completed - Pain Clinical Trials

Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metastases-related Pain in Patients With Prostate Cancer

TRAPEZE
Start date: June 2005
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of 4 mg zoledronic acid administered intravenously every 3-4 weeks in the treatment of bone metastases-related pain in patients with prostate cancer.

NCT ID: NCT00375245 Completed - Neoplasm Metastasis Clinical Trials

Rapamycin With Grapefruit Juice for Advanced Malignancies

Start date: September 2006
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the highest safe dose of rapamycin when given with a fixed amount of grapefruit juice.

NCT ID: NCT00375154 Withdrawn - Clinical trials for ARF Secondary to COPD Exacerbation

HERMES STUDY: Study on the Feasibility and Efficiency of Noninvasive Positive-Pressure Ventilation (NPPV) in Prehospital Care

Start date: August 2006
Phase: N/A
Study type: Interventional

The purpose of this study is determine if NPPV can be performed in a pre-hospital setting very early after onset of dyspnea with a similar benefit in need of intubation and mortality as in previous study in hospital context and if early NPPV intervention have a real, rather standard medical therapy, value, both on objectively measured parameters and on patient's clinical status.

NCT ID: NCT00374751 Completed - Pain Clinical Trials

Effect of Samarium on the Relief of Pain Due to Vertebral Metastases

Start date: May 2006
Phase: Phase 1/Phase 2
Study type: Interventional

Cancer cells may spread from the primary site to the vertebrae resulting in their deformity. The standard treatment for this case is removal of the cancer deposits in the vertebra and filling the induced cavity with a cement like substance. The investigators are studying the effects (good or bad) of adding samarium (a radioactive substance) to the cement that is injected into the induced cavity.

NCT ID: NCT00374036 Completed - Neoplasm Metastasis Clinical Trials

Metastatic Gastric Cancer FFCD 03-07

Start date: June 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effectiveness of 2 different sequences of polychemotherapy among carrying patients of a adenocarcinoma of the stomach or cardia locally advanced or metastatic.

NCT ID: NCT00369785 Completed - Brain Tumors Clinical Trials

Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors

Start date: February 2008
Phase: Phase 3
Study type: Interventional

RATIONALE: Donepezil may help lessen confusion and fatigue and improve mood and quality of life in patients who have undergone radiation therapy for brain tumors. It is not yet known whether donepezil is more effective than a placebo in lessening side effects of radiation therapy in patients with brain tumors. PURPOSE: This randomized phase III trial is studying donepezil to see how well it works in lessening side effects of radiation therapy compared with a placebo in patients who have undergone radiation therapy for brain tumors.